Clinical Trial Search

Primary: Change in 24-hr Proteinuria With Dapagliflozin for Six Weeks Relative to Placebo in Patients With Non-diabetic Kidney Disease and Proteinuria 500 mg/Day on Stable…

Primary: Number of Subjects With Normal Urinary Protein Excretion in Healthy and Diabetic Children, Assessed Over 1 Day. — 91; 112 participants — p=<0.05

Primary: Number of Participants With Adverse Events — 0; 11; 60 Participants

Primary: Urinary Protein/Creatinine Ratio at Week 52 [LOCF] — 0.938; 1.082; 0.759 ratio

Primary: Urinary Protein/Creatinine Ratio in Patients With Type 1 or 2 Diabetes. — 1.016; 0.955; 0.874 mg/g

Primary: Percentage Change in Proteinuia — -23; -4 % change from baseline

Primary: Percent Change in Estimated Glomerular Filtration Rate (eGFR) at Visit 12 — -24.927; -20.563; -17.447 percent change

Primary: Patients With Reduced or Resolved Proteinuria — 20 participants

Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr

Primary: Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12 — -35.80; 1.37 Percent Change in Pr/Cr — p=0.001

Primary: 24-hour Urine Albumin Excretion — 86.2; 76.4 mg/day — p=0.05

Primary: Change in Proteinuria by 25% — 8 Participants

Primary: The Change in Urinary Protein/Creatinine Ratio From Baseline to 28 Weeks — 794.0; 639.9; 819.0 mg/g

Primary: Changes in Log-transformed Urinary Albumin-to-creatinine Ratio (UACR) at Week 12 — -0.10; -0.15; -0.53 Log(mg/g) — p=0.7953

Primary: Percentage of Participants With Complete or Partial Remission in Proteinuria at 24 Weeks — 1; 5; 2; 0 Participants

Primary: Change From Baseline in Average Systolic Blood Pressure at 8 Weeks — -1.5; -1.8; 0.5 mmHg

Primary: Percentage of Participants Who Had Initiated Losartan Therapy at 52 Weeks Following Conversion to SRL — 6.2; 23.2 percentage of participants — p=0.0002

Primary: Normalized Protein Catabolic Rate (nPCR) — 1.038; 0.930 g/(kg*d)

Primary: Change in Proteinuria — 4.56; 1.36 ratio

Primary: Bladder Diary to Assess Urinary Frequency at Baseline and at End of 6-week Treatment — 12.32; 10.79 urinations/day — p=0.19

Primary: Change in Urine Microalbumin Creatinine Ratio — 15 mg/g

Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine

Primary: Number of Subjects Developing Microalbuminuria During Study Period — 35 Participants

Primary: Number of Participants Meeting the Definition of Responder for Reduction in Proteinuria at the Indicated Time Points — 0; 1; 0; 0 Participants

Primary: Reduction in Proteinuria in Recurrent FSGS Following Renal Transplant With Plasma Exchange and Cyclophosphamide. — 0; 0; 0.5; 0.25 proportion of participants with…

Primary: Energy Expenditure — 2045; 2343 kcal

Primary: Part B:Change From Baseline in Proteinuria — 1.5; -0.4; 0.1; 0.7 grams per 12 hour (g/12 hour) — p=0.0449

Primary: Changes in Urine Albumin to Creatinine Ratio (UACR) — -64.6; 104.8 mg/g — p=0.279

Primary: Number of Participants With Weight<10th Percentile for Age — 32; 41 Participants

Primary: Number of Participants With a Reduction in Proteinuria at 6 Months by > 50% of the Value at Screening AND Stable GFR Defined as Greater Than 75 ml/Min/1.73m2 in Those…